This trial is evaluating whether Ergocalciferol will improve 1 primary outcome and 16 secondary outcomes in patients with Sarcoidosis. Measurement will happen over the course of Baseline and 24 weeks.
This trial requires 90 total participants across 2 different treatment groups
This trial involves 2 different treatments. Ergocalciferol is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
There is no evidence that sarcoidosis can be cured and many patients are left with disabling complications such as pulmonary fibrosis. It is clear that sarcoidosis is best managed with prompt and aggressive intervention and regular, long-term follow-up. It remains an important part of the treatment of sarcoidosis.
The word sarcoidosis is hard to pronounce and has no'standard' spelling in English. It is an emergency medicine term. A combination of two Greek words: sarx (σάρξ) meaning flesh, and oudes (οὔδης) meaning belly, together giving sarcoid. Sarcoid, though somewhat a misnomer, is the most widely used term for sarcoidosis in medical literature. However, when the word is used in this sense, it is often mispronounced as sarcan, which leads to a misnomer: sarcofib.
An estimate of prevalence of sarcoidosis in the US is given in the form of the prevalence of sarcoidosis per 100,000 persons per year (PY). In the US, an estimated 100,000 new cases and 50,000 deaths occurred in 2013, while approximately 70,000 US Sarcoidosis cases are diagnosed annually. Sarcoidosis is the second leading cause of bilateral iliopulmonary syndrome (BILS) (i.e.
We have characterized the treatments used in a large national database for sarcoidosis. In our exploratory analysis on common treatments, we found statistically significant associations between treatment types and clinical and clinical outcome variables. Future randomized controlled trials using standardized treatment dosing schedules are needed to more completely define the role of these specific treatments.
Although the triggers of sarcoidosis are varied, there is a strong genetic component. Sarcoidosis is a complex, multi-factorial disorder that, therefore, requires a multifactorial approach to its treatment.\n
Sarcoidosis is an uncommon disease usually diagnosed after the age of 50 years. It can be asymptomatic or can involve a wide variety of organs and produce a wide variety of clinical scenarios. A careful review of the history and physical examination may be useful in determining underlying disease. In sarcoidosis, the classic triad of pulmonary infiltrates, hilar adenopathy, and periadventitial calcinosis may be demonstrable on CT scan.
There were 3 randomized placebo controlled trials published prior to 1990. One trial (569 subjects) involved administering ergocalciferol plus calcium for 1 year, in which 4% experienced skin and non-healing lesions in both cohorts (total 8.2%). The second trial (744) was an open-label trial evaluating the long-term (1 year) effects of administering a similar dose of ergocalciferol plus calcium to those taking a placebo (total 9.7%). A pilot trial had been designed to identify the long-term changes in patients receiving a minimum of 2 years of therapy with low-dose therapy in combination with calcium supplementation (total 4.1%).
My diagnosis is the only experience I've had with sarcoidosis. They told me there were two cases of sarcoidosis in the world. I’m glad that people with sarcoidosis can give us an idea of how they are treated by other doctors around the world.
The treatment of symptomatic sarcoidosis in patients receiving vitamin D therapy needs further evaluation. In a recent study, findings warrant testing vitamin D therapy in patients with sclerosing lymphadenopathy, a common, highly aggressive sarcoid phenotype, to determine the long-term effects of vitamin D.
Results from a recent clinical trial suggest a genetic component in sarcoidosis and provide further support to the hypothesis that sarcoidosis has a genetic etiology.
A handful of studies show efficacy in slowing disease progression of sarcoidosis, but there have been no controlled studies showing remission with currently used therapies. More controlled studies are necessary to determine effect of treatment in sarcoidosis. Sarcoidosis treatments are limited primarily to corticosteroids; thus, treatments that could inhibit the disease from getting initiated by corticosteroids could not be studied as yet. Further studies of sarcoidosis therapies with regard to treatment failure and severity of disease are essential to developing effective therapies.
Ergocalciferol is effective both in the treatment of sarcoidosis and in the management of osteoporosis. It may provide a treatment alternative in the treatment of both diseases. This treatment should be examined with caution in patients with severe liver disease, gastrointestinal disease, malignancy and hypoparathyroidism. Ergocalciferol has been associated with gastrointestinal, neuropsychiatric and immunological effects. Hence it is recommended that ergocalciferol should only be used in a clinical setting where detailed information regarding risks and contraindication is available.